CD307B抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD307B mouse mAb (green) and negative control (red).    

  
  

CD307B, also known as Fc receptor-like protein 5 (FCRL5), is a member of the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks binding affinity for immunoglobulins. Expressed predominantly on B cells, particularly memory B cells and plasma cells, CD307B is implicated in regulating B-cell activation, differentiation, and immune responses. Its extracellular region contains immunoglobulin-like domains, while its cytoplasmic tail features immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), suggesting dual regulatory roles in signaling pathways.

CD307B has garnered attention for its potential involvement in autoimmune diseases, infections, and B-cell malignancies. Studies highlight its upregulated expression in conditions like rheumatoid arthritis, systemic lupus erythematosus (SLE), and chronic lymphocytic leukemia (CLL), where it may modulate pathogenic antibody production or cell survival. Additionally, CD307B serves as a marker for atypical memory B cells in malaria and HIV, linking it to chronic antigen exposure.

Therapeutic interest in CD307B arises from its restricted expression on abnormal B-cell subsets, making it a candidate for targeted therapies. Antibodies against CD307B are being explored for diagnostic applications, drug delivery, and engineered CAR-T cell therapies. However, its precise ligand interactions and signaling mechanisms remain under investigation, necessitating further research to clarify its role in immune regulation and disease pathogenesis.